Product Information
DABIGATRAN ETEXILATE 150 MG CP is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.7946 per EA under NDC 00378026691. Its NADAC has been published 79 times since Apr 2, 2025.
FDA first approved this application on Feb 3, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The Low Outlier badge above means this manufacturer's average price in the Dabigatran Etexilate market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
150 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378026691
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DABIGATRAN ETEXILATE MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA208067FDA Approved
2/3/2025
TE Code
AB
On Market Since
2/25/2025
Pharmacological Classes
Price Statistics
The NADAC for DABIGATRAN ETEXILATE 150 MG CP has been published 79 times since Apr 2, 2025, and over the history we have for it it has declined 51.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7946 per EA |
|---|---|
| All-time high | $1.6485 (Apr 16, 2025) |
| All-time low | $0.7946 (Sep 23, 2026) |
| 52-week high | $1.1459 |
| 52-week low | $0.7946 |
| Median price | $0.9827 |
| Average price | $1.0829 |
| Largest weekly change | -9.3% (Sep 17, 2025) |
| Weeks tracked | 79 |
| Tracking since | Apr 2, 2025 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Dabigatran Etexilate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Direct Thrombin Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DABIGATRAN ETEXILATE 150 MG CP?
The current National Average Drug Acquisition Cost (NADAC) for DABIGATRAN ETEXILATE 150 MG CP, manufactured by Mylan Pharmaceuticals Inc., is $0.7946 per EA (NDC 00378026691), effective Sep 30, 2026.
How has the price of DABIGATRAN ETEXILATE 150 MG CP changed over time?
Over the history we have for it, the NADAC for DABIGATRAN ETEXILATE 150 MG CP has declined 51.8%. It has been tracked across 79 weekly CMS publications since Apr 2, 2025.
What are the highest and lowest recorded NADAC prices for DABIGATRAN ETEXILATE 150 MG CP?
Since Apr 2, 2025, the NADAC for DABIGATRAN ETEXILATE 150 MG CP has ranged from a low of $0.7946 (Sep 23, 2026) to a high of $1.6485 (Apr 16, 2025), with a median of $0.9827 per EA.
Are there cheaper alternatives to DABIGATRAN ETEXILATE 150 MG CP?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as DABIGATRAN ETEXILATE 150 MG CP in a comparable dosage form, but none are currently priced below it.
Who manufactures DABIGATRAN ETEXILATE 150 MG CP?
DABIGATRAN ETEXILATE 150 MG CP (NDC 00378026691) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.